Previous studies have shown that IDO1 and 2 can suppress anti-tumor immune response by activating CD4+CD25+Foxp3+ regulatory T cells (Treg) (14, 55–57) and myeloid-derived suppressor cells (MDSCs) (58), which consequently inactivate CTLs. Here, IDO1 is linked to neoplasm.